It's not developing drugs that bind to RNA, or morphing RNA into a therapeutic — this Cambridge startup has scored $63M to work on RNA-modifying proteins
First came the concept of epigenetics, the study of chemical modifications made to the blueprint of life — DNA — to switch genes on or off. Then, scientists realized DNA’s cousin RNA could also be subject to such chemical manipulation, and the field of “epitranscriptomics” was born in the last decade.
As researchers found that chemical modifications across a cell’s RNA were seemingly distorted in some cancers, a trio of biotechnology companies spawned: Storm Therapeutics, Accent Therapeutics and Gotham Therapeutics. On Thursday, 2017-founded Accent raised $63 million in a Series B round, led by EcoR1 Capital.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.